Seminars in Immunopathology最新文献

The cancer-microbiome axis: Mechanisms and emerging therapeutic strategies. 癌症-微生物组轴：机制和新兴的治疗策略。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2026-04-16 DOI: 10.1007/s00281-026-01072-1

Maria Rae Walker, Marlene Schwarzfischer, Michael Scharl

引用次数: 0

Cytokine-mediated, organ-specific immune modulation and dysregulation of innate lymphocytes in sepsis. 脓毒症中细胞因子介导的器官特异性免疫调节和先天淋巴细胞失调。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2026-04-10 DOI: 10.1007/s00281-026-01071-2

Seoyeon Han, Sejong Bae, Seungwon Ryu

引用次数: 0

Butyrate remodels the immune-epigenetic-gut-lung axis: Emerging mechanisms and therapeutic perspectives in asthma. 丁酸重塑免疫-表观遗传-肠-肺轴：哮喘的新机制和治疗前景。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2026-04-06 DOI: 10.1007/s00281-026-01069-w

Yuqia Xie, Guochun Huang, Jun Zhao, Zhicheng Yuan, Hangyu Li, Jingyi Deng, Daichi Chen, Wenlu Zhu, Gonghua Huang, Yuanhui Li, Suidong Ouyang

引用次数: 0

Effect of the intestinal microbiota on T_H17 cell-derived cytokines in the context of intestinal inflammation. 肠道微生物群对肠道炎症背景下TH17细胞源性细胞因子的影响

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2026-04-02 DOI: 10.1007/s00281-026-01070-3

Justus Neuendorff, Samuel Huber, Penelope Pelczar

引用次数: 0

Paneth cells as orchestrators of epithelial barrier defense and emerging therapeutic targets in inflammatory bowel disease. Paneth细胞作为上皮屏障防御的协调者和炎症性肠病的新治疗靶点。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2026-03-16 DOI: 10.1007/s00281-026-01068-x

Lena Erkert, Lea-Maxie Haag, Christoph Becker

引用次数: 0

Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT. 新兴的微生物组导向治疗炎症性肠病：超越饮食改变和FMT。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2025-11-25 DOI: 10.1007/s00281-025-01066-5

Andrea Carolina Quiroga-Centeno, Konstantina Atanasova, Matthias Philip Ebert, Anne Kerstin Thomann, Wolfgang Reindl

{"title":"Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT.","authors":"Andrea Carolina Quiroga-Centeno, Konstantina Atanasova, Matthias Philip Ebert, Anne Kerstin Thomann, Wolfgang Reindl","doi":"10.1007/s00281-025-01066-5","DOIUrl":"10.1007/s00281-025-01066-5","url":null,"abstract":"Inflammatory bowel disease (IBD) is a multifactorial and heterogeneous disorder that remains challenging to manage. Growing evidence implicates the gut microbiome as a key player in IBD pathogenesis, with many patients displaying intestinal dysbiosis that can drive aberrant immune responses. Traditional microbiome-targeted interventions, such as dietary modifications, probiotics, and fecal microbiota transplantation (FMT), have yielded mixed and often temporary benefits in IBD. This shortcoming of broad-spectrum approaches underscores the need for more precise, personalized strategies that account for each patient's unique microbiota and disease phenotype. Recent advances in omics and bioengineering have catalyzed the development of emerging microbiome-directed therapies that move beyond these broad approaches. This narrative review highlights emerging microbiome-directed therapies that aim to restore gut homeostasis and mitigate inflammation in IBD. We critically evaluate the rationale and therapeutic potential of rationally designed bacterial consortia and genetically engineered bacteria, which represent next-generation probiotics tailored to complement deficient microbial functions or deliver anti-inflammatory agents in situ. We also expand the discussion to underexplored microbiome constituents - archaea, protists, bacteriophages, and fungi - highlighting their roles in IBD and potential as therapeutic targets. Finally, we discuss the key advances and ongoing challenges of these innovative approaches, from ecological stability and engraftment to safety and regulatory considerations.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"47 1","pages":"42"},"PeriodicalIF":9.2,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12647200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145605657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The microbiome's hidden influence: preclinical insights into inflammatory responses in necrotizing enterocolitis. 微生物组的隐藏影响：坏死性小肠结肠炎炎症反应的临床前观察。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2025-11-24 DOI: 10.1007/s00281-025-01059-4

Briana M Peterson, Ina Rudloff, Nadia S Deen, Sara K Di Simone, Ramesh M Nataraja, Gergely Toldi, Maurizio Pacilli, Steven P Garrick, Steven X Cho, Marcel F Nold, Samuel C Forster, Claudia A Nold-Petry

{"title":"The microbiome's hidden influence: preclinical insights into inflammatory responses in necrotizing enterocolitis.","authors":"Briana M Peterson, Ina Rudloff, Nadia S Deen, Sara K Di Simone, Ramesh M Nataraja, Gergely Toldi, Maurizio Pacilli, Steven P Garrick, Steven X Cho, Marcel F Nold, Samuel C Forster, Claudia A Nold-Petry","doi":"10.1007/s00281-025-01059-4","DOIUrl":"10.1007/s00281-025-01059-4","url":null,"abstract":"Necrotizing enterocolitis (NEC) is the most common surgical emergency in preterm infants; nonetheless, besides supportive measures, no treatment is available. NEC significantly increases length of hospitalization of preterm infants, causes severe morbidity and up to 70% mortality. Despite limited understanding of the underlying mechanisms, prematurity, dysbiosis and an underdeveloped immune system are known to increase the risks of developing NEC. The low weight of preterm infants (often < 2000 g) and unpredictable progression of NEC hinder clinical research; hence, most of our mechanistic understanding of NEC pathophysiology has arisen from animal models. Recent advances in bacterial genomic analyses highlighted the intestinal microbiome's key role in NEC, strengthening the concept that this disease results from an interaction between the patient's developing immune system and their microbiome. This notion is supported by the moderate effect of probiotics in preventing NEC. Here, we review the current knowledge on how the immune system interacts with the intestinal microbiome in early life, including in relation to NEC, describe the current evidence from cohort studies, clinical trials, in vivo and in vitro models used to study NEC, and methods to modulate the immune system and microbiome in early life. Knowledge on the early-life microbiome and immune system in health and diseases, including NEC, can be harnessed to develop novel and urgently needed immunomodulatory and microbiota-based therapeutics.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"47 1","pages":"41"},"PeriodicalIF":9.2,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12644200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145588954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Therapeutic mechanisms of exclusive enteral nutrition in crohn's disease. 纠正：单独肠内营养治疗克罗恩病的机制。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2025-11-11 DOI: 10.1007/s00281-025-01067-4

Tina Krammel, Jiatong Nie, Deborah Häcker, Tobias Schwerd, Doriane Aguanno, Dirk Haller

引用次数: 0

Systemic sclerosis: pathogenic mechanisms and their implications for treatment. 系统性硬化症：发病机制及其治疗意义。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2025-11-11 DOI: 10.1007/s00281-025-01065-6

Alain Lescoat, Valérie Lecureur, Johann E Gudjonsson, Dinesh Khanna

{"title":"Systemic sclerosis: pathogenic mechanisms and their implications for treatment.","authors":"Alain Lescoat, Valérie Lecureur, Johann E Gudjonsson, Dinesh Khanna","doi":"10.1007/s00281-025-01065-6","DOIUrl":"10.1007/s00281-025-01065-6","url":null,"abstract":"Systemic sclerosis (SSc) is a rare systemic autoimmune disease characterized by a triad of pathogenic mechanisms, including: a) microvascular hyperreactivity secondary to endothelial dysfunction, b) dysregulated immune activation of both innate and adaptive immunity, with the production of autoantibodies targeting nuclear antigens (e.g., anticentromere antibodies, anti-RNA polymerase III antibodies, and anti-topoisomerase I antibodies), and c) fibrosis of the skin and internal organs, such as the lungs, due to excessive extracellular matrix deposits produced by dysregulated myofibroblasts. Skin involvement plays a crucial role in the detrimental impact of SSc on quality of life. Skin fibrosis in SSc is characterized by the progressive accumulation of extracellular matrix components, including collagen, in the dermis, and is associated with adipocyte atrophy in the hypodermis. Visceral manifestations include fibrotic interstitial lung disease (ILD), myocardial involvement, pulmonary arterial hypertension, gastrointestinal manifestations, and scleroderma renal crisis. These manifestations are key determinants of prognosis and significant contributors to mortality in SSc. This review will explore the clinical features of SSc, the existing subtypes based on different classification approaches (such as skin-driven classifications, autoantibodies, or molecular subsets), epidemiology, identified etiologies, pathogenesis, current standards of care, and a selection of potential therapeutic perspectives. This review will emphasize SSc-related skin manifestations, including their pathogenesis and treatment, while also discussing other organ manifestations.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"47 1","pages":"39"},"PeriodicalIF":9.2,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment. 坏疽性脓皮病：发病机制及其治疗意义。

IF 9.2 2区医学

Seminars in Immunopathology Pub Date : 2025-10-23 DOI: 10.1007/s00281-025-01064-7

Chiara Moltrasio, Maurizio Romagnuolo, Gianluca Tavoletti, Carlo Alberto Maronese, Angelo Valerio Marzano

{"title":"Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment.","authors":"Chiara Moltrasio, Maurizio Romagnuolo, Gianluca Tavoletti, Carlo Alberto Maronese, Angelo Valerio Marzano","doi":"10.1007/s00281-025-01064-7","DOIUrl":"10.1007/s00281-025-01064-7","url":null,"abstract":"Pyoderma gangrenosum (PG) is a rare inflammatory skin disease belonging to the group of neutrophilic dermatoses. The pathogenesis of PG involves a predisposing genetic background that facilitates a dysregulated innate and adaptive immune response, with an imbalance between pro-inflammatory and anti-inflammatory mediators, leading to neutrophil-driven inflammatory damage. Several immunosuppressants and immunomodulatory drugs are currently available for the treatment of PG, in combination with topical therapies, wound management and pain control strategies. Systemic corticosteroids and cyclosporine remain the first-line treatment options with the best evidence. However, in recent years, the rise of knowledge about different pathogenic mechanisms has led to a significant increase in studies attesting the efficacy and safety of biologic therapies including, among others, antagonists of tumour necrosis factor (TNF)-α and interleukin (IL)-23, becoming the drug of choice in specific clinical setting. Similarly, different small molecules such as JAK-STAT (Janus kinase/signal transducer and activator of transcription) inhibitors are showing promising results for the treatment of PG. We review established and emerging pathogenesis-driven treatments, also providing a therapeutic algorithm and informing future directions in the management of PG.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"47 1","pages":"38"},"PeriodicalIF":9.2,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12549756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0